Clinical Research
Research studies
HIV clinical trials at OIC
Explore our HIV clinical trials and Phase I-IV research in treatment and prevention, hepatitis, vaccines, and emerging infectious diseases.
Now enrolling
4 studies are open to new participants
CD388 · Long-Acting Flu Prevention Study
CD388 is a new kind of antiviral designed to help protect against the flu for an entire season with a single dose. The active part of an existing antiviral, zanamivir, is attached to a portion of a human monoclonal antibody so the investigational product stays in the body for about six months. Researchers want to know whether it can help prevent influenza, and whether it can reduce symptom severity if someone gets the flu anyway. This is OIC’s first-ever influenza study, a new area of research for our team. Route: three subcutaneous injections given on Day 1 (back of the arm, abdomen, and thigh). Length: about 197 days (plus or minus 7), not counting up to 21 days of screening, with 5 in-person visits and 3 phone calls. Compensation: $150 per completed on-site visit, plus $10 per e-diary entry ($50 per entry during the ARI portion of the study). You can still get your regular seasonal flu shot after enrolling, as long as it wasn’t within 14 days before Day 1. Adults and adolescents at higher risk of flu complications may qualify, including people living with HIV who have a CD4 count of 350 or below. Protocol: CD388.SQ.3.06 · Phase 3 · Sponsor: Cidara Therapeutics
I’m interested →Gilead-5938 · Daybreak-1: Twice-Yearly HIV Treatment
Daybreak-1 compares a new, twice-yearly HIV medication combination with an already-approved option given every two months. Group 1 receives two antibody medications, teropavimab and zinlirvimab, together with the antiviral lenacapavir, dosed only twice a year. Group 2 receives cabotegravir and rilpivirine, an injectable combination already used in HIV care, given every 8 weeks. It’s for adults whose HIV is currently well controlled on a daily pill and who are interested in far less frequent dosing. Route: Group 1 takes an oral loading dose on Day 1, then receives the medication by subcutaneous injection and IV infusion; Group 2 receives intramuscular injections. Length: 92 weeks, with an optional 2-year extension phase. Compensation: $100 per completed scheduled or unscheduled visit, $300 for infusion visits. Protocol: GS-US-536-5938 (Daybreak-1) · Phase 3 · Sponsor: Gilead Sciences
I’m interested →Gilead-6544 · Daybreak-2: Twice-Yearly HIV Treatment
Daybreak-2 is a companion study to Daybreak-1, exploring the same twice-yearly medication combination for people whose HIV is already well controlled on a stable daily pill. Group 1 switches to teropavimab and zinlirvimab plus lenacapavir, dosed only twice a year. Group 2 continues on its current stable oral regimen. It’s for adults interested in trying a far less frequent dosing schedule while researchers gather more safety and effectiveness information. Route: Group 1 takes an oral loading dose on Day 1, then receives the medication by subcutaneous injection and IV infusion; Group 2 continues its stable baseline regimen. Length: 92 weeks. Compensation details are provided during screening. Protocol: GS-US-536-6544 (Daybreak-2) · Phase 3 · Sponsor: Gilead Sciences
I’m interested →Gilead-6557 · Pulsar-2: HIV Treatment for Newly Diagnosed Adults
Pulsar-2 is for adults who are newly diagnosed with HIV and haven’t yet started treatment. The study compares an investigational injectable regimen, GS-3242 combined with lenacapavir, with Biktarvy, a daily oral tablet (bictegravir, emtricitabine, and tenofovir alafenamide) that is a standard treatment option today. Researchers want to know whether the injectable regimen controls HIV as well as the daily pill, with less frequent dosing. Route: injectable regimen for the investigational group; daily oral tablet for the comparison group. Length: 52 weeks, with an optional 2-year extension phase. Compensation: $100 per completed scheduled or unscheduled visit, $100 per completed additional injection, $30 per completed phone call visit, and $400 for an optional PK sub-study visit on Day 1. Protocol: GS-US-643-6557 (Pulsar-2) · Phase 2/3 · Sponsor: Gilead Sciences
I’m interested →Full directory